中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Viral Hepatitis
NASH
HIV/AIDS
Pipeline & Products
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
Presentation Materials
News
Careers
Investors
Financials & Filing
Presentation Materials
Voluntary Announcement - Proposed Share Repurchase under the Repurchase Mandate
2020-09-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2020
2020-09-04
2020 Interim Results
2020-08-28
Voluntary Announcement - Completion of Bridging Study of ASC18
2020-08-20
Voluntary Announcement - First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, A Subcutaneously Administered PD-L1 Antibody
2020-08-17
Notice of Board Meeting
2020-08-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2020
2020-08-05
Voluntary Announcement - Approval for Marketing All-oral HCV Treatment
2020-07-31
Voluntary Announcement - Bridging Study in China Completed for NASH Drug Candidate ASC40
2020-07-20
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2020
2020-07-03
«
3
4
5
6
»